Malignancy risk in patients with atopic dermatitis: a population-based cohort study.

Autor:	Wan J; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Shin DB; Departments of Dermatology., Syed MN; Departments of Dermatology., Abuabara K; Department of Dermatology, University of California San Francisco, San Francisco, CA, USA., Lemeshow AR; Pfizer, Inc., New York, NY, USA., Fuxench ZCC; Departments of Dermatology., Gelfand JM; Departments of Dermatology.; Biostatistics, Epidemiology and Informatics; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Jazyk:	angličtina
Zdroj:	The British journal of dermatology [Br J Dermatol] 2023 Jul 07; Vol. 189 (1), pp. 53-61.
DOI:	10.1093/bjd/ljad072
Abstrakt:	Background: Atopic dermatitis (AD) is associated with immunological dysfunction, which may influence cancer development. Previous studies of AD and cancer demonstrate inconsistent results and few of these studies examined children or AD severity and treatment. Objectives: To determine malignancy risk among children and adults with AD. Methods: We conducted a cohort study using electronic health records data from UK general practices in The Health Improvement Network between 1994 and 2015. Children (< 18 years old) and adults (≥ 18 years old) with AD were matched on age, practice and index date to patients without AD. AD was categorized as mild, moderate or severe using treatments and dermatology referrals as proxies. The primary outcome was any incident malignancy, including in situ malignancy, identified using diagnosis codes and categorized into haematological, skin and solid organ malignancies. Secondary outcomes included specific malignancies: leukaemia, lymphoma, melanoma, nonmelanoma skin cancer (NMSC) and common solid-organ cancers. Results: Among 409 431 children with AD (93.2% mild, 5.5% moderate, 1.3% severe) and 1 809 029 children without AD who had median follow-up of 5-7 years, the incidence rates of malignancy were 1.9-3.4 and 2.0 per 10 000 person-years (PY), respectively. The adjusted risk of malignancy overall did not differ with respect to AD [hazard ratio (HR) 1.02 (95% confidence interval 0.92-1.12)]. Severe AD was associated with increased lymphoma risk [HR 3.18 (1.41-7.16), excluding cutaneous T-cell lymphoma (CTCL)], and mild AD was associated with increased NMSC risk [1.55 (1.06-2.27)]. Among 625 083 adults with AD (65.7% mild, 31.4% moderate, 2.9% severe) and 2 678 888 adults without AD who had median follow-up of 5 years, incidence rates of malignancy were 97.4-125.3 per 10 000 PY and 103.7 per 10 000 PY, respectively. The adjusted risk of any malignancy did not differ with respect to AD [HR 1.00 (0.99-1.02)]. However, adults with severe AD had a twofold higher risk of non-CTCL lymphoma. AD was also associated with slightly higher skin cancer risk [HR 1.06 (1.04-1.08)] and slightly lower solid cancer risk [0.97 (0.96-0.98)] but results varied by specific cancers and AD severity. Conclusions: Epidemiological evidence does not support a strong overall malignancy risk in AD but lymphoma risk may be increased with severe AD. Competing Interests: Conflicts of interest J.W. has received research and fellowship funding from Pfizer, Inc. (paid to Johns Hopkins University). M.N.S. has received fellowship funding from Pfizer, Inc. (paid to the University of Pennsylvania). K.A. has received research funding from Pfizer, Inc. and L’Oréal (paid to University of California San Francisco), and receives consulting fees for serving on the academic steering committee for TARGET RWE. A.R.L. is an employee of Pfizer, Inc. Z.C.C.F. has received research grants from LEO Pharma, Lilly, Regeneron, Sanofi, Tioga and Vanda for work related to atopic dermatitis and from Galderma and Menlo Therapeutics for work related to prurigo nodularis. She has also served as consultant for the Asthma and Allergy Foundation of America, National Eczema Association, AbbVie, Incyte Corporation and Pfizer; and received honoraria for CME work in Atopic Dermatitis sponsored by education grants from Pfizer and Regeneron/Sanofi and from Beirsdorf for work related to skin cancer and sun protection. J.M.G. has served as a consultant for Abbvie, Abcentra, BMS, Boehringer Ingelheim, GSK, Janssen Biologics, Lilly (DMC), Mindera Dx, Neuroderm (DSMB), Novartis Corp, Trevi and UCB (DSMB) receiving honoraria; and receives research grants (to the Trustees of the University of Pennsylvania) from Boehringer Ingelheim and Pfizer Inc.; and received payment for continuing medical education work related to psoriasis that was supported indirectly by pharmaceutical sponsors; is a co-patent holder of resiquimod for the treatment of cutaneous T-cell lymphoma; serves as a Deputy Editor for the Journal of Investigative Dermatology receiving honoraria from the Society for Investigative Dermatology; is Chief Medical Editor for Healio Psoriatic Disease (receiving honoraria); and is a member of the Board of Directors for the International Psoriasis Council, receiving no honoraria. D.B.S. has no disclosures to report. (© The Author(s) 2023. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu